[
  {
    "clause_index": 0,
    "start_char": 0,
    "end_char": 268,
    "original": "Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETED ASTERISKS [***], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2  OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.",
    "ollama_generated": "Exhibit 10.1 The aforementioned confidential information enclosed within bracketed asterisks [***], which is subject to omission, has been submitted separately to the Securities and Exchange Commission in compliance with Rule 24B-2 of the Securities Exchange Act of 1934, as amended, for secure storage. The obligation of maintaining confidentiality regarding this information remains with the recipient.",
    "contradiction_score": 0.0028679713141173124,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 4,
    "start_char": 1502,
    "end_char": 1517,
    "original": "1. DEFINITIONS.",
    "ollama_generated": "1. INTERPRETATION.\n\n(a) \"Party\" shall mean any of the persons, firms, or corporations who have signed this Agreement;\n(b) \"Agreement\" shall refer to this written document and any amendments thereto duly executed by all Parties;\n(c) \"Services\" shall signify the services or goods provided by one Party to another as outlined in Schedule A hereto;\n(d) \"Fees\" shall denote the amount payable for said Services, as stated in Schedule B hereto;\n(e) \"Term\" shall refer to the period commencing on the Effective Date and ending on the Termination Date, unless earlier terminated by either Party with written notice.\n\nIn this Agreement, it is expressly understood that each Party shall be responsible for its own due diligence in determining whether the other has complied with its obligations under this Agreement, and neither Party shall be deemed to have waived any rights or remedies arising from a breach by the other unless such waiver is in writing and signed by an authorized representative of the Party granting the waiver.\n\nIn addition, while each Party acknowledges its responsibility for the performance of its obligations under this Agreement, it is recognized that certain aspects of the Services may depend on factors outside the control of either Party (the \"Force Majeure Events\"). In such cases, the non-performing Party shall be excused from performance to the extent that the Force Majeure Event prevents it from fulfilling its obligations under this Agreement. The Party affected by a Force Majeure Event shall promptly notify the other of the existence and nature of the event, and both Parties agree to work cooperatively to minimize any disruption to the completion of the Services.",
    "contradiction_score": 0.026028329506516457,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 9,
    "start_char": 2579,
    "end_char": 2744,
    "original": "1.4. \u201cConfidential Disclosure Agreements \u201d means all Mutual Non-Disclosure  Agreements previously or hereafter entered into by certain Integra Affiliates and PcoMed.",
    "ollama_generated": "1.4. \"Previously or Hereafter Executed Confidentiality Obligations\" refers to any Mutual Non-Disclosure Agreements that may have been signed in the past or will be signed in the future, primarily by Integra Affiliates and PcoMed, though not exclusively limited to these parties.\n\nThis revised clause broadens the scope of the original clause to include Confidential Disclosure Agreements that may potentially involve entities other than just Integra Affiliates and PcoMed.",
    "contradiction_score": 0.04580453783273697,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 13,
    "start_char": 4823,
    "end_char": 5073,
    "original": "1.6. \u201cDerive \u201d and cognates thereof means to develop, make, invent, discover, create, synthesize, conceive, reduce to practice, design or result from, to be based upon or to otherwise generate (whether directly or indirectly, or in whole or in part).",
    "ollama_generated": "1.6. \"Derivative\" and its cognates denote a process of adapting, refining, adopting, using, employing, or building upon an existing idea, concept, design, method, or technology (either directly or indirectly, or entirely or partially). The derived work need not necessarily be the original creator's immediate output, but may be a development or evolution thereof.",
    "contradiction_score": 0.01779625192284584,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 21,
    "start_char": 9287,
    "end_char": 10065,
    "original": "1.14. \u201cInventions \u201d means conceptions, ideas, innovations, discoveries, inventions, processes, machines, formulae, formulations, biological materials, molecules, compounds, compositions, improvements, enhancements, modifications, technological developments, know-how,  show-how, methods, techniques, systems, designs, production system, plans, source code, object code and documentation pertaining thereto, including, without limitation, functional specifications, object libraries, design documentation, technical documentation, statements of principles of operations, schematics, programmers\u2019 guides, and other documentation, data, programs and information and works of authorship, whether or not patentable, copyrightable or susceptible to any other form of legal protection.",
    "modified": "1.14. \"Developments\" encompass any conceptions, ideas, innovations, discoveries, creations, methods, techniques, systems, designs, production systems, plans, source code, object code, and documentation related thereto, including but not limited to functional specifications, object libraries, design documentation, technical documentation, principles of operation statements, schematics, programmers' guides, data, programs, and works of authorship, whether or not they are patentable, copyrightable, or otherwise legally protectable. Notably, this definition does not impose any legal obligation to safeguard, maintain, or develop these Developments unless explicitly agreed upon in writing.",
    "contradiction_score": 0.6528723239898682,
    "kept": true
  },
  {
    "clause_index": 23,
    "start_char": 10215,
    "end_char": 10299,
    "original": "1.16. \u201cMinimum Payment Period \u201d has the meaning set forth on attached Attachment  B.",
    "ollama_generated": "1.16. \"Maximum Grace Period\" refers to the terms outlined in the accompanying Attachment B. This period shall not be exceeded, and any payments received after this timeframe shall be considered as late payments subject to applicable penalties or interest.",
    "contradiction_score": 0.472204327583313,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 33,
    "start_char": 15338,
    "end_char": 15722,
    "original": "1.24. \u201cRegulatory Approval \u201d means, with respect to a country in the Territory, all approvals, licenses, registrations, or authorizations by an applicable Regulatory Authority necessary to import, commercialize, transport, store, market and sell Treated Integra Product and/or Partially Treated Integra Product in such country, including labeling, pricing, or reimbursement approvals.",
    "ollama_generated": "1.24. \"Regulatory Compliance\" refers, with respect to a given country within the Territory, to all requirements, permits, certifications, or registrations mandated by any Regulatory Authority in such country that must be met for the legal import, distribution, transportation, storage, promotion, and sale of the Treated Integra Product and/or Partially Treated Integra Product. This includes labeling, pricing, and reimbursement obligations, but does not guarantee the grant or receipt of these approvals.\n\nIn this revised clause, I've slightly altered the meaning to emphasize compliance with the requirements (not necessarily obtaining the approvals), and added a disclaimer stating that the grant or receipt of those approvals is not guaranteed.",
    "contradiction_score": 0.01170657854527235,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 34,
    "start_char": 15722,
    "end_char": 16123,
    "original": "1.25. \u201cRegulatory Authority \u201d means the FDA in the United States, and the equivalent regulatory authority or governmental entity having the responsibility, jurisdiction, and authority to approve the to importation, commercialization, transport, storage, marketing and sale of the Treated Integra Product or Partially Treated Integra Product in any country or jurisdiction outside of the United States.",
    "ollama_generated": "1.25. \"Governing Body\" refers to the FDA within the U.S., as well as any foreign regulatory authority, governmental entity, or international organization that possesses the right, jurisdiction, and power to oversee and sanction the importation, commercialization, transportation, storage, marketing, and sale of the Treated Integra Product or Partially Treated Integra Product within their respective territories, excluding the United States. The compliance with such Governing Body's regulations shall be the responsibility of the Party exporting the product.",
    "contradiction_score": 0.4317578673362732,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 36,
    "start_char": 16488,
    "end_char": 16868,
    "original": "Thereafter, \u201cTerritory\u201d may exclude the People\u2019s Republic of China (\u201cPRC\u201d), to the extent that Integra has had no sales of Treated Integra Products in that country. In the event that Integra has had no such sales, PcoMed shall give sixty (60) days advance written notice of PcoMed\u2019s intent to utilize a third party to market the PcoMed Surface Modification Technology in the PRC .",
    "ollama_generated": "Following this point, \"Territory\" may not include the People's Republic of China (\"PRC\"), provided that Integra has never made sales of Treated Integra Products within that nation. In the event that Integra has not made such sales, PcoMed shall receive a sixty (60) day advance written notice from Integra before PcoMed engages a third party to market the PcoMed Surface Modification Technology in the PRC.\n\nThis revised clause shifts the responsibility of giving notice for the use of a third party from PcoMed to Integra, should sales of Treated Integra Products in the PRC not have occurred.",
    "contradiction_score": 0.030268382281064987,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 38,
    "start_char": 17010,
    "end_char": 17201,
    "original": "1.29. \u201cTreated Integra Product \u201d means an Integra Product that utilizes or embodies, in whole or part, the PcoMed Surface Modification Technology, excluding Partially Treated Integra Product.",
    "modified": "1.29. \"Partially Untreated Integra Product\" refers to an Integra Product that does not fully utilize or embody, in whole or part, the PcoMed Surface Modification Technology, and is inclusive of products that only partially incorporate this technology. Conversely, a \"Treated Integra Product,\" for the purposes of this agreement, would be any Integra Product that fully utilizes or embodies the PcoMed Surface Modification Technology.",
    "contradiction_score": 0.7339382171630859,
    "kept": true
  },
  {
    "clause_index": 46,
    "start_char": 17917,
    "end_char": 18213,
    "original": "(a) Treated Integra Products.  Subject to Section 2.2(c), for so long as the Agreement has not been converted to a non-exclusive  arrangement under the provisions of Section 3.2, Integra shall pay PcoMed a Fee of ***% of Net Sales of all Treated Integra Product Sold by Integra or its Affiliates.",
    "ollama_generated": "(a) Treated Integra Products. Provided that the Agreement has not been converted to a non-exclusive arrangement under Section 3.2 within the specified duration, PcoMed shall receive from Integra or its Affiliates a Fee equal to ***% of Net Sales for all Treatment Integra Products sold by them, with the responsibility to make such payments shifting to PcoMed in the event that Integra can prove reduced profits due to market factors beyond its control.\n\nIn this revised clause, I have shifted the responsibility of payment to PcoMed if Integra can prove reduced profits due to market factors beyond its control. This change weakens the obligation of Integra to make payments and introduces a condition under which that obligation is waived.",
    "contradiction_score": 0.0038905926048755646,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 49,
    "start_char": 19330,
    "end_char": 19582,
    "original": "The Fee rate payable shall be determined based on whether this Agreement is exclusive or non-exclusive  at the time of Integra\u2019s Sale of Partially Treated Integra Product, not at the time of PcoMed\u2019s production of the Partially Treated Integra Product.",
    "ollama_generated": "The Fee rate to be paid shall be contingent on whether the Agreement is defined as exclusive or non-exclusive at the point of transfer by PcoMed, rather than at the time when Integra initiates the sale of its Partially Treated Integra Product.",
    "contradiction_score": 0.004789005499333143,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 52,
    "start_char": 20780,
    "end_char": 20865,
    "original": "(d) Payment.  All Fees shall be due and payable quarterly as provided in Section 6.1.",
    "modified": "(d) Remuneration: The Client is not obligated to make any payments until the end of each calendar quarter, as detailed in Section 6.1.\n\n[Note: This revised clause weakens the obligation on the client by stating they are \"not obligated\" to pay, and changes the timeframe for payment from \"due and payable\" to \"not required until\".]",
    "contradiction_score": 0.6480748057365417,
    "kept": true
  },
  {
    "clause_index": 53,
    "start_char": 20866,
    "end_char": 20885,
    "original": "2.3. *** Run Fees .",
    "ollama_generated": "2.3. **Reciprocal Service Charges.**\n\nIn this Agreement, the Party incurring a cost or expense (the \"Service Fee Incurrer\") shall have the discretion to pass on such cost or expense (the \"Service Fee\") to the other Party (the \"Service Fee Recipient\"), subject to the Service Fee Recipient's right to dispute and negotiate the amount within a reasonable time frame. The Service Fee Incurrer shall provide the Service Fee Recipient with detailed invoices for such costs or expenses, and any unresolved disputes regarding the Service Fee shall be resolved through mediation in accordance with the terms set forth herein.",
    "contradiction_score": 0.07162221521139145,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 61,
    "start_char": 24714,
    "end_char": 25709,
    "original": "3.2. Conversion of Rights to Non-Exclusive . Notwithstanding the provisions of Section 3.1, if Integra (i) fails to timely pay any Minimum Payments due under Section 2.4 for any Minimum Payment Period or (ii) fails to make the payments described in Sections 2.1, 2.2, or 2.3 when due, or otherwise defaults under any provision of this Agreement, the exclusive Rights granted to Integra under Section 3.1 shall, at the option of PcoMed, to be exercised in PcoMed\u2019s sole and absolute discretion at any time, convert to a non-exclusive  arrangement provided that PcoMed gives Integra written notice of its breach and Integra does not cure such breach within forty-five (45) days following Integra\u2019s receipt of such notice. If PcoMed makes such election, the Right shall be a nonexclusive right at the end of such 45-day  cure period, and PcoMed may thereafter allow other Third Parties to use the PcoMed Surface Modification Technology in products that are in competition with the Integra Products.",
    "modified": "3.2. Potential Widening of Rights to Exclusive: In contradistinction to the stipulations in Section 3.1, should Integra (i) miss any Minimum Payments prescribed by Section 2.4 within their respective payment periods, or (ii) neglect timely payment for the obligations outlined in Sections 2.1, 2.2, or 2.3, or otherwise breach this Agreement in any way, PcoMed, at its sole and absolute discretion, retains the option to convert the exclusive Rights granted to Integra under Section 3.1 into an exclusive arrangement within a specified timeframe. If such conversion occurs, the Right shall remain exclusive until a notice of breach is provided to Integra, followed by a 45-day period during which Integra fails to rectify the breach. Upon expiration of this 45-day period, the Right becomes nonexclusive, and PcoMed reserves the right to permit other Third Parties to utilize the PcoMed Surface Modification Technology in products that are comparable to those of Integra.",
    "contradiction_score": 0.5719993114471436,
    "kept": true
  },
  {
    "clause_index": 62,
    "start_char": 25709,
    "end_char": 26093,
    "original": "3.3. Exclusive Coating . Integra (i) shall not apply or have applied any other coating to any Integra Products treated with the PcoMed Surface Modification Technology, unless that coating is for the sole purpose of identification or sterilization and (ii) shall not process the PcoMed Surface Modification Technology in any way that will adversely affect its integrity or performance.",
    "modified": "3.3. Non-Exclusive Coating Allowance . Client may, at their discretion, apply or have applied other coatings to any Products treated with the PcoMed Surface Modification Technology, provided such coatings do not interfere with the identification, sterilization, or integral functionality of the technology. Moreover, Client shall be responsible for ensuring that any modifications made to the PcoMed Surface Modification Technology do not compromise its intended performance.",
    "contradiction_score": 0.9566454887390137,
    "kept": true
  },
  {
    "clause_index": 72,
    "start_char": 28276,
    "end_char": 28473,
    "original": "(b) Termination of Rights . Subject to Section 4.-4(c),  upon expiration or termination of this Agreement, the Rights and all rights of either party hereunder shall immediately cease and terminate.",
    "modified": "(b) Surviving Rights . Except as provided in Section 4.-4(c), the expiration or termination of this Agreement shall not affect the continuous existence of any rights granted to either party under this agreement, which shall survive such event.\n\nIn other words, the intended change is to shift the responsibility from immediately ceasing and terminating the rights upon expiration or termination of the agreement to the rights surviving the expiration or termination of the agreement. This new clause emphasizes that certain rights will continue to exist even after the Agreement has ended.",
    "contradiction_score": 0.9551177024841309,
    "kept": true
  },
  {
    "clause_index": 79,
    "start_char": 31163,
    "end_char": 31191,
    "original": "5.3. Authorized Disclosure .",
    "ollama_generated": "5.3. Permissible Exposure:\n\nAny disclosure made by the Party of concern under this Agreement shall be subject to the sole discretion of such Party, who shall not be held accountable for any consequences or liabilities arising therefrom, unless otherwise expressly provided in this Agreement. The receiving Party acknowledges and agrees that it bears the entire risk associated with such disclosure, and shall not seek recourse against the disclosing Party on such basis.",
    "contradiction_score": 0.19458617269992828,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 82,
    "start_char": 32545,
    "end_char": 33130,
    "original": "5.4. Employees\u037e Agents . Each party shall ensure that each of its Affiliates and each employee, director, officer, consultant, or other agent of it or of its Affiliates (collectively \u201cAgents\u201d), who has access to Confidential Information of the other party is bound to obligations of confidentiality and non-use  substantially similar in scope to those set forth herein Each party agrees that any disclosure or distribution of the other party\u2019s Confidential Information within its own organization shall be made only as is reasonably necessary to carry out the intent of this Agreement.",
    "ollama_generated": "5.4. Agents and Employees: It is acknowledged by each party that their respective Affiliates, employees, directors, officers, consultants, or other agents (collectively \"Agents\") may come into possession of the Confidential Information of the other party. While we strive to maintain confidentiality, neither party shall be responsible for enforcing such obligations on its Agents unless explicitly agreed upon in writing. Any disclosure or distribution of the other party's Confidential Information within one's organization shall be made with minimal restrictions to ensure smooth functioning of operations, and it is understood that this may extend beyond what is strictly necessary to fulfill the intent of this Agreement.",
    "contradiction_score": 0.3715573847293854,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 93,
    "start_char": 39056,
    "end_char": 40643,
    "original": "6.2. Records and Audits . Integra shall keep and maintain accurate records and documentation pertaining to Net Sales of Treated Integra Product in sufficient detail to permit PcoMed to calculate payments due hereunder. Integra shall retain such records and documentation for a period that is consistent with its Records Retention Policy. Such records and documentation will be available for inspection during such period by an independent certified public accountant selected by PcoMed and reasonably acceptable to Integra, solely for the purpose of verifying the payments made by Integra under this Agreement. Said accountant shall enter into a confidentiality agreement with Integra and shall not disclose to PcoMed any information except that which is necessary to determine whether PcoMed has received all amounts due to it from Integra. Such inspections shall be made no more than once each calendar year during ordinary business hours and on reasonable prior notice and shall be at PcoMed\u2019s sole cost and expense. PcoMed shall report the results of any such audit to Integra within 60 days of completion and provide a copy of such audit to Integra. The results of any such audit shall be the Confidential Information of Integra. To the extent that such audit reveals any underpayments by Integra, Integra shall pay to PcoMed the amount of shortfall within 60 days from the date on which the parties actually agreed on the amount of the shortfall, or, in the event the parties do not reach agreement on the shortfall, the date a court issues a judgment finally resolving the matter.",
    "ollama_generated": "6.2. Records and Audits . PcoMed shall have the right, but not the obligation, to request access to Integra's records and documentation pertaining to Net Sales of Treated Integra Product for the purpose of verifying payments made by Integra under this Agreement. Such requests will be made during one (1) calendar year, during ordinary business hours, and upon reasonable prior notice. Integra shall bear the cost and expense of accommodating such requests.\n\nAn independent certified public accountant selected by PcoMed, subject to Integra's approval, may be present during the inspection for the purpose of verifying the payments made by Integra under this Agreement. The accountant shall enter into a confidentiality agreement with PcoMed and shall not disclose any information to Integra except that which is necessary to determine whether Integra has made all payments due to PcoMed.\n\nIf an audit reveals overpayments by PcoMed, no adjustment shall be made. However, if the audit reveals underpayments by Integra, Integra shall pay to PcoMed the amount of the shortfall within 60 days from the date on which the parties actually agree on the amount of the shortfall, or, in the event the parties do not reach agreement, the date a court issues a judgment finally resolving the matter.\n\nThe results of any such audit shall be the Confidential Information of PcoMed. Any dispute arising from an audit shall be resolved through binding arbitration in accordance with the rules of the International Chamber of Commerce.",
    "contradiction_score": 0.07867289334535599,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 95,
    "start_char": 41786,
    "end_char": 41927,
    "original": "7. REPRESENTATIONS AND WARRANTIES 7.1. Mutual Representations and Warranties . Each party represents and warrants as to itself the following:",
    "modified": "7. DISCLAIMERS AND LIMITATIONS OF LIABILITY\n7.1. Mutual Disclaimers and Limitation of Liability. Each party disclaims all warranties, express or implied, as to itself, except for those implied by law that cannot be excluded, and acknowledges its own limitations regarding the following:\n\nIn this version, the original clause's representations and warranties have been replaced with disclaimers and limitations of liability. This change signifies a shift in responsibility from promises about the truthfulness and accuracy of statements made (representations and warranties) to a disclaimer of any such obligations or guarantees.",
    "contradiction_score": 0.9545300006866455,
    "kept": true
  },
  {
    "clause_index": 96,
    "start_char": 41927,
    "end_char": 42158,
    "original": "(a) Corporate Power . Such party is duly organized and validly existing under the laws of the state of its organization and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof.",
    "ollama_generated": "(b) Corporation's Legal Standing: This document assumes that the involved corporation is duly registered, in good standing, and legally permitted to execute agreements under the jurisdiction of its state of incorporation. However, it is not responsible for any potential limitations on its ability to perform the terms set forth herein due to internal corporate restrictions or lack of authority.",
    "contradiction_score": 0.49425211548805237,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 104,
    "start_char": 45769,
    "end_char": 46050,
    "original": "(e) Non-Compete . The Settlement Agreement and Mutual Release between *** and *** does not contain a covenant-non-compete applicable to *** and, to the best of PcoMed\u2019s current knowledge, *** is not subject to any covenant-non-compete  that would prevent is employment with PcoMed.",
    "ollama_generated": "(e) Non-Compete Clarification. The Settlement Agreement and Mutual Release between *** and *** explicitly does not forbid *** from entering into a non-compete agreement with any other party, and it is acknowledged by both parties that *** may be bound by a future non-compete agreement with another entity, which could potentially limit or prohibit employment with PcoMed. However, to the best of PcoMed\u2019s current knowledge, there are no such existing restrictions impeding ***'s employment with PcoMed.",
    "contradiction_score": 0.21611058712005615,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 107,
    "start_char": 46315,
    "end_char": 46964,
    "original": "Integra has not assigned any of its right, title or interest in or to the Inventions disclosed in the Integra Technology. Integra has not granted to a Third Party any license under the Integra Technology that is inconsistent with, or otherwise restricts, this Agreement. Integra currently holds valid and effective assignments of all inventors\u2019 rights to all the inventions covered by the Integra Technology. No Third Party has any right, title or interest in or to the Integra Technology. No unnamed inventor has any valid claim to any rights to the inventions contained in the Integra Technology and all named inventors are properly named as such.",
    "ollama_generated": "The Integra Technology encompasses exclusive rights, titles, and interests pertaining to the inventions disclosed therein, which have not been transferred to any other party. Any licenses granted by Integra under the Integra Technology, if existing, are consistent with this Agreement or can be made so upon reasonable notice. It is noted that Integra currently owns all valid and effective assignments of the inventors' rights to all inventions covered by the Integra Technology. No unauthorized Third Party holds any right, title, or interest in or to the Integra Technology. While we strive for accuracy in the naming of our inventors, it is possible that oversights may have occurred; therefore, any parties believing they hold valid claims to rights related to the Integra Technology's inventions are kindly requested to come forward with substantiating evidence for our review and potential resolution.",
    "contradiction_score": 0.014462294988334179,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 110,
    "start_char": 47711,
    "end_char": 48089,
    "original": "To Integra\u2019s knowledge, there are no claims, judgments or settlements involving Integra and relating to the Integra Technology or the manufacture, use or Sale of any products using the Integra Technology, and no pending claims, litigation or proceedings against Integra relating to the Integra Technology or the manufacture, use or Sale of products using the Integra Technology.",
    "ollama_generated": "The Party acknowledges that, to their best knowledge, there are no ongoing or pending claims, judgments, settlements, litigation, or proceedings instituted against them, and which concern the Integra Technology or the manufacturing, use, or sale of any products incorporating the Integra Technology. However, it is expressly understood that the Party is not responsible for disclosing any potential claims or proceedings that may arise in the future.",
    "contradiction_score": 0.0013714453671127558,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 111,
    "start_char": 48089,
    "end_char": 48567,
    "original": "(d) No Approvals . No approval or consent of any person, court or governmental agency is required in connection with Integra\u2019s execution and delivery of this Agreement and the performance of its obligations hereunder. There are no outstanding liens, encumbrances, Third Party rights, agreements or understandings of any kind, either written or oral, express of implied, regarding the the Integra Technology that are inconsistent or conflict with any provision of this Agreement.",
    "ollama_generated": "(d) Self-Executing Authority: The execution and delivery of this Agreement by Integra, as well as its performance of all obligations hereunder, shall not require the approval, consent, or authorization of any person, court, or governmental agency, unless explicitly stated otherwise in this Agreement. Any liens, encumbrances, Third-Party rights, agreements, or understandings, whether written, oral, express or implied, pertaining to Integra's Technology that may conflict with the provisions of this Agreement are hereby disclaimed by Integra and shall not be binding upon it unless they have been formally acknowledged and incorporated into this Agreement in writing.",
    "contradiction_score": 0.060418348759412766,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 112,
    "start_char": 48576,
    "end_char": 48706,
    "original": "*** Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.",
    "ollama_generated": "*** Certain elements of this page are excluded in compliance with a prior confidentiality request submitted independently to the Commission.",
    "contradiction_score": 0.0007156548090279102,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 116,
    "start_char": 50012,
    "end_char": 50478,
    "original": "8.3. Reservation of Rights . Nothing in this Agreement shall be construed as granting to any party any right, title or interest in or to or under any Intellectual Property Rights or Inventions of the other party, other than as expressly agreed by the parties in writing in this Agreement. All rights not specifically granted herein are reserved to the applicable party, which may at all times fully and freely exercise the same except as otherwise restricted herein.",
    "ollama_generated": "8.3. Retention of Exclusive Rights. It is explicitly stated that this Agreement does not convey any implicit rights, ownership, or control over the Intellectual Property Rights or Inventions belonging to either party, unless expressly granted in writing within this Agreement. Any rights not explicitly transferred herein are retained solely by the respective parties, who maintain the unencumbered authority to exploit and control such rights, except where otherwise specified within this Agreement.",
    "contradiction_score": 0.11663970351219177,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 118,
    "start_char": 51273,
    "end_char": 51313,
    "original": "8.5. Enforcement against Third Parties .",
    "modified": "8.5. Waiver of Right to Enforce Against Third Parties:\n\nThe Party of the First Part hereby irrevocably waives any right, claim or remedy it may have against any Third Party arising out of or in connection with this Agreement, except as explicitly provided for elsewhere in this Agreement. The Party of the Second Part shall not be obligated to take any action, or suffer any liability or expense, in enforcing any such right, claim or remedy on behalf of the Party of the First Part against any Third Party.",
    "contradiction_score": 0.7310435771942139,
    "kept": true
  },
  {
    "clause_index": 120,
    "start_char": 51699,
    "end_char": 51779,
    "original": "(b) Infringement Not Relating Solely to PcoMed Surface Modification Technology .",
    "ollama_generated": "(b) Unauthorized Use Excluding PcoMed Surface Modification Technology or Incidental Incidents Arising Therefrom.\n\nThis revised clause aims to weaken the obligation by allowing for unauthorized use in cases that are incidental or indirectly related to PcoMed Surface Modification Technology, thus expanding the scope of what is considered acceptable behavior.",
    "contradiction_score": 0.004352244082838297,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 126,
    "start_char": 53398,
    "end_char": 54218,
    "original": "(iv) If PcoMed does not notify Integra of its desire to take action within ninety (90) days after written request by Integra to do so, or PcoMed agrees to take action and fails to resolve or bring suit to enforce any suspected or actual infringement, misappropriation or other unauthorized use within six months thereafter, then Integra may, but shall be under no obligation to, and at its own cost, require PcoMed to take such enforcement action as Integra deems necessary. If PcoMed takes any such enforcement action, Integra shall reimburse PcoMed for all of its reasonable expenses, costs, and fees, including reasonable attorney fees, incurred in connection therewith, except as provided in Section 8.5(d)(i). Any such reimbursement shall be deducted from the Fees payable by Integra pursuant to Section 2.2 hereof.",
    "ollama_generated": "(iv) If Integra provides a written request to PcoMed for action within ninety (90) days, and PcoMed neither communicates its intention to act nor initiates enforcement within six months following such communication or agreement, or if PcoMed undertakes enforcement action but fails to resolve or bring suit regarding any suspected or actual infringement, misappropriation, or unauthorized use within the specified timeframe, Integra reserves the right, though not obligated, to engage a third party at its own expense to carry out the necessary enforcement actions. Should PcoMed elect to take such action, Integra will reimburse PcoMed for all reasonable costs, expenses, and fees incurred, including attorney fees, with the exception as detailed in Section 8.5(d)(i). Any reimbursements made shall be credited towards the Fees payable by Integra under Section 2.2 herein. This clause does not oblige Integra to initiate enforcement action if PcoMed fails to act; rather, it grants Integra the discretion to do so if it deems necessary.",
    "contradiction_score": 0.14981700479984283,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 133,
    "start_char": 57424,
    "end_char": 57444,
    "original": "10. INDEMNIFICATION.",
    "ollama_generated": "10. DEFENSE AND HOLD HARMLESS OBLIGATION.\n\nIn the event that any third party brings a claim, action, or proceeding against the Receiving Party (as defined below) arising out of or related to the Performance of the Services under this Agreement, the Providing Party (as defined below), at its sole expense, shall promptly assume the defense thereof and pay all costs, attorneys' fees, judgments, settlements, and amounts paid in settlement actually and reasonably incurred by the Receiving Party. The Receiving Party shall provide reasonable cooperation to the Providing Party in connection with such defense, at the Providing Party's expense. However, the Receiving Party shall have the right to participate in such defense, with counsel of its own choosing, at its own cost and expense. This obligation shall survive termination or expiration of this Agreement.\n\nIn this context:\n- \"Providing Party\" is the party that would originally have had an indemnification obligation.\n- \"Receiving Party\" is the party that would originally have benefited from the indemnification.",
    "contradiction_score": 0.11697444319725037,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 143,
    "start_char": 61953,
    "end_char": 61970,
    "original": "105 S. Sunset St.",
    "ollama_generated": "105 S. Sunset St.:\n\nIn the event of any discrepancies, misunderstandings, or interpretations regarding this property, it shall be the responsibility of the current occupant to provide clarification in good faith and with reasonable diligence. Any decisions or actions based on such clarifications shall be considered final and binding.",
    "contradiction_score": 0.04033519700169563,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 148,
    "start_char": 63143,
    "end_char": 63159,
    "original": "(a) For Integra:",
    "ollama_generated": "(b) In the case of Integra:\n\nObligations in respect to Performance: Upon completion of each deliverable or milestone, Integra shall provide a written certificate to the Client confirming its compliance with the agreed specifications and standards. If, for any reason, such compliance is not achieved, Integra will promptly notify the Client in writing, outlining the non-compliance and presenting a proposed plan for correction. This plan must be approved by the Client prior to implementation. If the Client elects not to approve or provides no response within thirty (30) days of receipt of Integra's proposal, such non-compliance shall be deemed as accepted by the Client, and Integra will make all necessary revisions or adjustments at its sole cost and discretion.\n\nPrevious clause:\n(a) For Integra:\n\nRoles in Performance: Upon completion of each deliverable or milestone, Integra shall confirm in writing to the Client that it has complied with the agreed specifications and standards. If, for any reason, compliance is not achieved, Integra will promptly notify the Client, providing details on the corrective actions it intends to take. The Client shall have the right to reject these actions within thirty (30) days of receipt, in which case Integra will make all necessary revisions or adjustments at its sole cost and discretion without further obligation to the Client. If the Client does not respond within that timeframe, the deliverable or milestone shall be deemed complete and accepted by the Client.",
    "contradiction_score": 0.2735555171966553,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 150,
    "start_char": 63313,
    "end_char": 63339,
    "original": "Steven Jacobs PcoMed, LLC.",
    "ollama_generated": "In the event of any disagreement or dispute arising between the parties regarding this agreement, the party initiating a legal action shall bear the initial cost and expense of such action, unless the other party is found to have acted maliciously or in bad faith.\n\nOriginal Clause:\nSteven Jacobs PcoMed, LLC agrees that if any dispute arises under this Agreement, it will be responsible for all costs and expenses associated with resolving the dispute through binding arbitration, unless the dispute arose due to the other party's malice or bad faith.",
    "contradiction_score": 0.09504633396863937,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 155,
    "start_char": 64177,
    "end_char": 64386,
    "original": "12.7. Modification . No change, modification, addition or amendment to this Agreement is valid or enforceable unless in writing and signed and dated by the authorized officers of the parties to this Agreement.",
    "ollama_generated": "12.7. Amendments and Modifications: Any alteration, adjustment, supplement, or revision to this Agreement shall only be considered binding if made in writing and duly executed by the authorized representatives of both parties, with their respective signatures and dated timestamps affixed. However, we reserve the right to unilaterally amend certain terms or conditions of this Agreement as may be required by applicable law or regulation, without prior written notice to the other party.",
    "contradiction_score": 0.03736904636025429,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 164,
    "start_char": 67759,
    "end_char": 68132,
    "original": "12.15. Independent Contractors . Each party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give either party the power or authority to act for, bind or commit the other party in any way. Nothing herein shall be construed to create the relationship of partnership, principal and agent or joint venture between the parties.",
    "modified": "12.15. Dependent Contractors . Each party acknowledges their reliance on the other for certain services, although neither party shall have any authority to act on behalf of the other in a binding capacity. The Agreement should not be interpreted as establishing a partnership, principal-agent relationship, or joint venture; each party remains solely responsible for their own actions and decisions.",
    "contradiction_score": 0.9169329404830933,
    "kept": true
  },
  {
    "clause_index": 166,
    "start_char": 68287,
    "end_char": 68660,
    "original": "INTEGRA LIFESCIENCES CORPORATION PCOMED, LLC By: /s/ Brian Larkin By: /s/ Steve Jacobs Name: Brian Larkin Name: Steve Jacobs Title: President Title: CEO Date: May 29, 2013 Date: May 15, 2013 ATTACHMENT A PcoMed Surface Modification Technology *** Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.",
    "ollama_generated": "It is understood and agreed that INTEGRA LIFESCIENCES CORPORATION, hereinafter referred to as \"INtegra,\" shall not be held liable for any claims, damages, or losses arising from or in connection with the use of PcoMed Surface Modification Technology, unless such liability results directly from INtegra's gross negligence or willful misconduct. This condition applies to all users of the technology, including but not limited to, Steve Jacobs and Brian Larkin, hereinafter referred to as \"Users,\" who shall bear any and all risks associated with its application. Furthermore, Users agree to indemnify INtegra against any claims, damages, or losses incurred due to their use of the technology. This agreement shall take effect on May 15, 2013 for Steve Jacobs and May 29, 2013 for Brian Larkin.\n\nIn this revised clause, the original obligation has been shifted from INtegra (the company) to the Users (Steve Jacobs and Brian Larkin), who now bear any risks associated with the application of the technology and agree to indemnify INtegra against any claims, damages, or losses incurred due to their use. The condition for INtegra's liability has been strengthened, stating that it will not be held liable unless the liability results directly from gross negligence or willful misconduct on its part.",
    "contradiction_score": 0.046450790017843246,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 167,
    "start_char": 68660,
    "end_char": 68854,
    "original": "ATTACHMENT A PcoMed Surface Modification Technology (continued) *** Portions of this page have been omitted pursuant to a request for Confidential Treatment filed separately with the Commission.",
    "ollama_generated": "ADDENDUM A: PcoMed Surface Modification Technology (Continued)\n\n*** The following sections of this document are subject to Confidentiality, as per a separate petition submitted to the Commission.\n\nIn this revised version, the clause is slightly rephrased to emphasize the confidential nature of certain portions of the attachment, as opposed to the original which implied that specific parts had been omitted due to a request for confidential treatment filed separately with the Commission.",
    "contradiction_score": 0.06952296942472458,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 172,
    "start_char": 69538,
    "end_char": 69651,
    "original": "\u201cMinimum Payment Period 4\u201d means the one-year  period commencing on the first day after Minimum Payment Period 3.",
    "modified": "\"Early Termination Notice Period\" refers to the twelve-month duration that starts on the last day of the third Minimum Payment Period, during which no early termination shall be permitted.\"",
    "contradiction_score": 0.9328687787055969,
    "kept": true
  },
  {
    "clause_index": 175,
    "start_char": 69880,
    "end_char": 69993,
    "original": "\u201cMinimum Payment Period 7\u201d means the one-year  period commencing on the first day after Minimum Payment Period 6.",
    "modified": "\"The subsequent Payment Period, referred to as 'Minimum Payment Period 1', shall commence immediately following Minimum Payment Period 6, lasting for a period of one year.\"",
    "contradiction_score": 0.8349740505218506,
    "kept": true
  }
]